Menu
Search
|

Menu

Close
X

Celyad SA CYAD.OQ (NASDAQ Stock Exchange Global Market)

41.82 USD
+0.12 (+0.29%)
As of 9:29 AM EST
chart
Previous Close 41.70
Open 41.82
Volume 239
3m Avg Volume 1,571
Today’s High 41.82
Today’s Low 41.82
52 Week High 64.00
52 Week Low 20.78
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.76
Price to Sales (TTM)
vs sector
--
8.59
Price to Book (MRQ)
vs sector
--
5.23
Price to Cash Flow (TTM)
vs sector
--
26.13
Total Debt to Equity (MRQ)
vs sector
--
15.32
LT Debt to Equity (MRQ)
vs sector
--
11.95
Return on Investment (TTM)
vs sector
--
13.59
Return on Equity (TTM)
vs sector
--
15.20

EXECUTIVE LEADERSHIP

Michel Lussier
Chairman of the Board, Co-Founder, Since 2007
Salary: --
Bonus: --
Christian Homsy
Member of the Executive Management Committee, Chief Executive Officer, Executive Director, Since 2007
Salary: --
Bonus: --
Patrick Jeanmart
Member of the Executive Management Committee, Chief Financial Officer, Since 2007
Salary: --
Bonus: --
Gaetane Metz
Chief Operating Officer, Since 2013
Salary: --
Bonus: --
Richard Mountfield
Vice President of Global Regulatory Affairs, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Rue Edouard Belin 12
MONT-SAINT-GUIBERT     1435

Phone: +3210.394100

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.

SPONSORED STORIES